Stock Evaluator: The Oncology Institute, Inc. (STLN)

The Oncology Institute, Inc. STLN

$5.14 -0.03 -0.58%
August 5, 2026 12:31:23 PM EST November 10, 2021 Volume: 340,364
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Health Care Providers & Services

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Starling Oncology, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-house infusion, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance and support services. It also manages clinical trials and palliative care programs; operates combined community clinics and infusion suites; and operates a specialty pharmacy that includes both in-office and mail-order dispensing for complementary oral and self-injectable medications taken by patients concurrent with their in-office cancer therapies. It serves adult and senior cancer patients. The company was formerly known as The Oncology Institute, Inc. and changed its name to Starling Oncology, Inc. in August 2026. Starling Oncology, Inc. was founded in 2007 and is headquartered in Cerritos, California.

Commentary & Analysis


Financial Summary

Share Statistics STLN Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $523.4 $1,880.0 38%
Shares Out (Mil) 101.8 79.2 63%
Institutional Ownership 78.4% 87.8% 48%
Float (Mil) 86.7 52.2 59%
Beta 0.36 0.83 21%
Avg Daily Volume (000s) 1,353 555 75%
Price Change
(52-week)
40.4% 79.5% 72%
Growth STLN Industry
Median
Percentile
(All Stocks)
Sales (5yr) 21.8% 10.8% 83%
Net Income (5yr) (33.5%) (0.3%) 12%
EPS (5yr) (17.6%) 3.1% 15
Dividends (5yr) 0.0% 0.0% 0%
Cash Flow (5yr) (37.0%) (18.0%) 13%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates na na na
Current EPS na na na
Month Ago EPS na na na
# Rev Up na na na
# Rev Down na na na
Three Months Ago EPS na na na
Year/Year Chg na na na
Financials STLN Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $546 $1,472 42%
Net Income (TTM) (Mil) ($44) $17 17%
EPS (TTM) ($0.369) $0.200 30%
Operating Cash Flow (TTM) (Mil) ($22) $139 14%
Net Cash Flow (TTM) (Mil) ($10) $7 31%
Long-Term Debt (Q1) (Mil) $98 $325 44%
Enterprise Value (Q1) (Mil) $476 $2,170 34%
Valuation STLN Industry
Median
Percentile
(All Stocks)
P/B na 2.81 na
P/E na 27.1 na
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) na 1.1 na
Ratios STLN Industry
Median
Percentile
(All Stocks)
Gross Margin 15.1% 27.8% 14%
Net Margin (8.0%) 1.1% 22%
ROA (26.2%) 1.9% 18%
ROE 775.9% 7.5% 100%
Liabilities to Assets 109.7% 59.9% 95%
F-Score na 5 %

The Oncology Institute, Inc. did not pass any screens on 8/4/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors